Enlivex Therapeutics Ltd. - Ordinary Shares, par value NIS 0.40 per share (ENLV)

Historical Holders from Q1 2019 to Q1 2025

Symbol
ENLV on Nasdaq
CUSIP
M4130Y106
Type / Class
Equity / Ordinary Shares, par value NIS 0.40 per share
Shares outstanding
22.6M
All holders as of December 31, 2024
Q4 2024
Shares, excl. options
3.41M
Holdings value
$3.99M
% of all portfolios
0%
Grand Portfolio weight change
+0%
Number of holders
25
Number of buys
17
Number of sells
-7
Average Value change %
+0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Enlivex Therapeutics Ltd. - Ordinary Shares, par value NIS 0.40 per share (ENLV)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ARMISTICE CAPITAL, LLC 9.75% $2.65M 2.21M Armistice Capital, LLC Dec 31, 2024

Institutional Holders of Enlivex Therapeutics Ltd. - Ordinary Shares, par value NIS 0.40 per share (ENLV)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q1 1K $971 -$11.7K $0.97 1
2024 Q4 3.41M $3.99M +$966K $1.17 25
2024 Q3 2.56M $4.31M +$807K $1.68 20
2024 Q2 2.08M $2.96M +$2.16M $1.42 17
2024 Q1 326K $1.24M +$436K $3.79 15
2023 Q4 188K $509K -$102K $2.70 17
2023 Q3 257K $407K -$97.1K $1.58 15
2023 Q2 302K $795K -$107K $2.63 20
2023 Q1 343K $1.24M +$17K $3.64 19
2022 Q4 337K $1.31M +$74.4K $3.92 21
2022 Q3 334K $1.41M -$1.41M $4.25 20
2022 Q2 605K $2.89M -$1.19M $4.52 21
2022 Q1 832K $4.65M +$923K $5.60 22
2021 Q4 662K $4.11M -$1.21M $6.24 19
2021 Q3 848K $8.38M -$1.35M $9.88 19
2021 Q2 988K $8.79M -$1.49M $8.90 21
2021 Q1 1.06M $11.7M +$7.35M $11.08 24
2020 Q4 398K $3.36M +$295K $8.43 11
2020 Q3 321K $1.91M -$157K $5.93 4
2020 Q2 355K $1.8M -$3.02M $5.05 7
2020 Q1 960K $4.49M +$3.96M $4.69 6
2019 Q4 80.2K $672K -$189K $8.37 4
2019 Q3 50.8K $1.36M +$783K $26.70 4
2019 Q2 21.4K $461K +$80.4K $21.47 2
2019 Q1 17.7K $219K +$219K $12.38 1